Scaling Digital Biomarker Discovery with the Cloud and Wearable Devices

In clinical trials and other disease research, biomarkers provide a valuable indication of drug performance and disease progression. Traditionally, these biomarkers may include genomic factors, lab test results, and more, but we now can easily expand into longitudinally collected digital biomarkers from consumer smart devices.

The Amissa platform, built on the Microsoft Azure cloud, enables the collection of high frequency data from consumer smartwatches (such as the Apple Watch and Samsung Galaxy watch devices). The API-driven cloud architecture enables secure sensor data collection including location, gyrometry/accelerometry, activity monitoring/pedometry, and biosensors such as oxygen saturation and heart rate. This solution allows for sub-minute capture frequency while balancing device battery drain. The ISO 27001:2013-compliant platform is globally scalable through an innovative cloud-native design that ensures security and compliance.

Caregivers, researchers, and healthcare providers can now monitor loved ones/patients through consumer-grade wearables, providing a cost-effective, accurate, and flexible solution for biomarker discovery, data collection, and remote monitoring.

The Amissa platform successfully enables digital biomarker development and helps to address disparities in clinical trials and research studies of underrepresented groups through decentralized data collection. Plus, the platform address security and privacy considerations while enables collaborative research participation and flexible study designs.